Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. This whitepaper will show leaders how strategic insights and targeted outreach can turn ...

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Gray Delany was pushed out due to disagreements with other top officials over how the Department of Health and Human Services ...

Skysona can now only be used in patients with cerebral adrenoleukodystrophy who have no available treatment alternatives or ...